Lantern Pharma: Using AI to Transform Drug Development

Lantern Pharma (Nasdaq: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The Company’s proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern Pharma has accelerated the development of its growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, Lantern Pharma’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program. Learn more at LTRNinfo.com.